I5T-MC-AACI – Assessment of Safety, Tolerability, and Efficacy of Donanemab
I5T-MC-AACI- Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease, Phase 3
$
This study is a 205-week study to test the effectiveness and safety of the study drug. You have a 50% chance of receiving study drug and a 50% chance of receiving a placebo. After 21 months of being on either study drug or placebo, if you were receiving a placebo, you will be put on the study drug.